Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVSEF) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • Novartis Ag's Consolidated Net Income fell 203.96% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.4 billion, marking a year-over-year increase of 1988.27%. This contributed to the annual value of $14.0 billion for FY2025, which is 1698.63% up from last year.
  • As of Q4 2025, Novartis Ag's Consolidated Net Income stood at $3.2 billion, which was down 203.96% from $4.2 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Consolidated Net Income peaked at $17.0 billion during Q4 2021, and registered a low of $46.0 million during Q2 2023.
  • Moreover, its 5-year median value for Consolidated Net Income was $3.2 billion (2021), whereas its average is $3.4 billion.
  • As far as peak fluctuations go, Novartis Ag's Consolidated Net Income crashed by 9910.92% in 2022, and later surged by 825000.0% in 2024.
  • Novartis Ag's Consolidated Net Income (Quarter) stood at $17.0 billion in 2021, then crashed by 99.11% to $151.0 million in 2022, then soared by 3768.87% to $5.8 billion in 2023, then crashed by 43.77% to $3.3 billion in 2024, then fell by 2.04% to $3.2 billion in 2025.
  • Its Consolidated Net Income stands at $3.2 billion for Q4 2025, versus $4.2 billion for Q3 2025 and $4.5 billion for Q2 2025.